Expand ZNTL Menu
ZNTL MENU

ZNTL Latest Press Releases

-- September 2, 2026 --

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences Globe Newswire 4:05 PM

-- September 1, 2026 --

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 5:15 PM

-- August 17, 2026 --

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares Globe Newswire 4:01 PM

-- August 13, 2026 --

Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering Globe Newswire 10:23 PM
Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering Globe Newswire 4:01 PM

-- August 6, 2026 --

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates Globe Newswire 4:05 PM

-- August 3, 2026 --

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 5:00 PM

-- July 17, 2026 --

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026 Globe Newswire 4:15 PM

-- June 1, 2026 --

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 5:00 PM

-- May 27, 2026 --

Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy Globe Newswire 4:05 PM

-- May 21, 2026 --

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 Globe Newswire 5:39 PM

-- May 13, 2026 --

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences Globe Newswire 4:05 PM

-- May 12, 2026 --

Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress Globe Newswire 4:05 PM

-- May 5, 2026 --

Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer Globe Newswire 8:00 AM

-- May 1, 2026 --

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 5:30 PM

-- April 21, 2026 --

Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer Globe Newswire 10:27 AM

-- April 17, 2026 --

Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026 Globe Newswire 3:15 PM
Market Data Delayed 15 Minutes